



# An intelligent exercise machine for measurable and motivational neuro-muscular rehabilitation therapy

## Fact Sheet


### Project Information

#### Enjoint

Grant agreement ID: 836465

[Project website](#) 

#### DOI

[10.3030/836465](https://doi.org/10.3030/836465) 

Project closed

#### EC signature date

4 December 2018

#### Start date

1 November 2018

#### End date

28 February 2019

#### Funded under

INDUSTRIAL LEADERSHIP - Innovation In SMEs

#### Total cost

€ 71 429,00

#### EU contribution

€ 50 000,00

#### Coordinated by

ROBOFIT APS



Denmark

## Objective

Annually 8.45 million of European citizens (~13% EU population) require some form of rehabilitation, and the number is expected to increase due to the aging, the proliferation of diseases and accidents.

Current rehabilitation devices fail to guarantee an effective therapy because of the lack of tailored training according to the patient needs, a therapist is required for each patient leading to long waiting lists, low self-training compliance, and the lack of

precise data about patient's evolution.

At Robofit ApS (2013, Denmark) we have been working on the new therapy generation: Enjoint. It is a novel intelligent exercise machine for neuro-muscular therapy, that using Big Data and Cloud Connection, provides precise data about patient progress while adjusting the rehabilitation training according to the patient injury and progress. Furthermore, it increases the compliance of the rehabilitation program through self-motivation of the patients thanks to its constant feedback. Enjoint current prototype is a fully functional device (hardware, software running on iOS, and cloud connection) optimized for neuro-muscular rehabilitation of shoulder joint and surrounding muscles. It has proved to reduce €132/patient per session, save €25,781/patient by reducing sickness period benefit, and to improve an 87.5% patient's compliance to the rehabilitation.

We expect to internationalise our customer base entering by 2021 onwards across Norway, Sweden, Finland, Germany, the UK and France. Expected gross profits after 3 years of commercial exploitation are estimated at €8.35 Million, serving more than 1,100 clinics across Europe. Successful implementation of this expansion project will result in growth of our company by up to 10 employees.

## Fields of science (EuroSciVoc)

[natural sciences](#) > [computer and information sciences](#) > **[software](#)**

[medical and health sciences](#) > [clinical medicine](#) > **[physiotherapy](#)**

[natural sciences](#) > [computer and information sciences](#) > [data science](#) > **[big data](#)**

[social sciences](#) > [political sciences](#) > **[government systems](#)**



## Programme(s)

[H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs](#)

MAIN PROGRAMME

[H2020-EU.3. - PRIORITY 'Societal challenges](#)

[H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies](#)

## Topic(s)

[EIC-SMEInst-2018-2020 - SME instrument](#)

## Call for proposal

[See other projects for this call](#)

## Sub call

H2020-SMEInst-2018-2020-1

## Funding Scheme

[SME-1 - SME instrument phase 1](#)

## Coordinator



### ROBOFIT APS

Net EU contribution

**€ 50 000,00**

Total cost

**€ 71 429,00**

Address

**MENGGARDVEJ 21  
6070 CHRISTIANSFELD**

 **Denmark** 

SME 

**Yes**

Region

**Danmark > Syddanmark > Sydjylland**

Activity type

**Private for-profit entities (excluding Higher or Secondary Education Establishments)**

Links

[Contact the organisation](#) 

[Participation in EU R&I programmes](#) 

[HORIZON collaboration network](#) 

**Last update:** 10 August 2022

**Permalink:** <https://cordis.europa.eu/project/id/836465>

